Patents Assigned to Amgen
  • SMARCA2-VHL DEGRADERS
    Publication number: 20230091042
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Application
    Filed: January 8, 2021
    Publication date: March 23, 2023
    Applicant: AMGEN INC.
    Inventors: Abhisek BANERJEE, Victor J. CEE, Ning CHEN, Xiaofen LI, Ryan Paul WURZ
  • Self-buffering antibody formulations
    Patent number: 11607451
    Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: March 21, 2023
    Assignee: Amgen Inc.
    Inventors: Yatin R. Gokarn, Eva Kras, Richard Louis Remmele, Jr., David Brems, Susan Irene Hershenson
  • Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
    Patent number: 11608344
    Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: March 21, 2023
    Assignees: AMGEN INC., VIGIL NEUROSCIENCE, INC.
    Inventors: Lara C. Czabaniuk, Timothy Hopper, Jonathan B. Houze, Jane Panteleev, Gwenaella Rescourio, Vincent Santora, Haoxuan Wang, Ryan D. White, Alice R. Wong, Yongwei Wu, Maxence Bos, John Mancuso, Ivan Franzoni
  • RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION
    Publication number: 20230078200
    Abstract: The present invention relates to RNAi constructs for reducing expression of the LPA gene, which encodes apolipoprotein(a), a component of lipoprotein(a) (Lp(a)) particles. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease, peripheral artery disease, stroke, and myocardial infarction, and to reduce serum Lp(a) levels are also described.
    Type: Application
    Filed: December 8, 2020
    Publication date: March 16, 2023
    Applicant: AMGEN INC.
    Inventors: Bin WU, Michael OLLMANN, Oliver HOMANN, Yuan CHENG
  • Treatment of acute lymphoblastic leukemia
    Patent number: 11597766
    Abstract: The present invention relates to a method for the treatment, amelioration or elimination of acute lymphoblastic leukemia (ALL), the method comprising the administration of a pharmaceutical composition comprising a CD19×CD3 bispecific single chain antibody construct to an adult patient in the need thereof.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: March 7, 2023
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Gerhard Zugmaier, Evelyn Degenhard
  • Methods for increasing mannose content of recombinant proteins
    Patent number: 11597959
    Abstract: The present invention relates to methods of upregulating the high mannose glycoform content of a recombinant protein during a mammalian cell culture by manipulating the mannose to total hexose ratio in the cell culture media formulation.
    Type: Grant
    Filed: December 14, 2020
    Date of Patent: March 7, 2023
    Assignee: Amgen Inc.
    Inventors: Chung-Jr Huang, Xiaoming Yang
  • Antibody constructs for DLL3 and CD3
    Patent number: 11591396
    Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising the polynucleotide and a host cell transformed or transfected with the polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of the antibody construct and a kit comprising the antibody construct.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: February 28, 2023
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Tobias Raum, Claudia Blümel, Christoph Dahlhoff, Patrick Hoffmann, Peter Kufer, Ralf Lutterbüse, Elisabeth Nahrwold, Jochen Pendzialek
  • Sheet lighting for particle detection in drug product containers
    Patent number: 11592403
    Abstract: In a method for imaging a container holding a sample, the container is illuminated with a laser sheet that impinges upon the container in a first direction corresponding to a first axis. A plane of the laser sheet is defined by the first axis and a second axis orthogonal to the first axis. The method also includes capturing, by a camera having an imaging axis that is substantially orthogonal to at least the first axis, an image of the container. The method further includes analyzing, by one or more processors, the image of the container to detect particles within, and/or on an exterior surface of, the container.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: February 28, 2023
    Assignee: AMGEN INC.
    Inventors: Thomas Clark Pearson, Graham F. Milne, Dmitry Fradkin, Erwin Freund
  • Syringe assembly for a drug delivery device and method of assembly
    Patent number: 11590294
    Abstract: A syringe assembly for a drug delivery device. The syringe assembly includes a syringe barrel having a proximal end, a distal end, and a longitudinal axis. A needle assembly is operatively coupled to the syringe barrel and includes a needle hub and a needle attached to the needle hub. A flexible connection is disposed between the syringe barrel and the needle hub and forms a fluid pathway between the syringe barrel and the needle. The flexible connection enables the needle assembly to be moveable from a filling position, in which a longitudinal axis of the needle assembly is parallel to a longitudinal axis of the syringe barrel, to an assembled position, in which the longitudinal axis of the needle assembly is not parallel to the longitudinal axis of the syringe barrel.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: February 28, 2023
    Assignee: AMGEN INC.
    Inventors: Adam B. McCullough, Hans Stenberg Knudsen, Rasmus Øhlenschlæger
  • Drug delivery device with activation prevention feature
    Patent number: 11590277
    Abstract: A wearable drug delivery device includes an injector having a housing, a reservoir, a needle or cannula, a drive mechanism for urging drug product out of the reservoir, through the needle or cannula, and to a patient, and an activator mechanism disposed on a surface of the housing for activating the drive mechanism. An activation prevention mechanism is coupled to the injector housing and/or activation prevention mechanism to prevent inadvertent actuation of the activator mechanism.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: February 28, 2023
    Assignee: AMGEN INC.
    Inventors: Brian Stonecipher, Margaux Frances Boyaval, James Chan, Avon Kuo, Allan Lee Cameron, Maxwell Franklin Bischoff, Gregg Allen Flender
  • ANTIBODIES DIRECTED TO HER-3 AND USES THEREOF
    Publication number: 20230059353
    Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
    Type: Application
    Filed: March 4, 2022
    Publication date: February 23, 2023
    Applicants: DAIICHI SANKYO EUROPE GMBH, AMGEN INC.
    Inventors: MIKE ROTHE, MARTIN TREDER, ERIC BORGES, LARRY GREEN, SUSANNE HARTMANN
  • Systems and methods for delayed drug delivery
    Patent number: 11583633
    Abstract: Systems and methods for delayed delivery of a drug are disclosed. A drug delivery system may include a delivery member for insertion into a patient and a reservoir configured to receive a volume of a drug. An energy source may be activatable by the patient to actuate the reservoir to deliver the drug to the patient as a single bolus. A lockout system may be configured to have a locked state, wherein the lockout system prevents movement of the delivery member and/or activation of the energy source, and an unlocked state, wherein the lockout system permits movement of the delivery member and/or activation of the energy source. The lockout system may be configured to automatically change from the locked state to the unlocked state after a preselected time period has elapsed. An output element may generate a detectable output after the preselected time period has elapsed for notifying the patient.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: February 21, 2023
    Assignee: AMGEN INC.
    Inventors: Scott Robert Gibson, Adam B. McCullough
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20230052348
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: October 14, 2021
    Publication date: February 16, 2023
    Applicant: AMGEN INC.
    Inventors: Sean P BROWN, David Karl BEDKE, Michael R. DEGRAFFENREID, Jiasheng FU, Zhinghong LI, Felix GONZALEZ LOPEZ DE TURISO, Ana GONZALEZ BUENROSTRO, Michael W. GRIBBLE JR., Michael G. JOHNSON, Todd J. KOHN, Kexue LI, Yunxiao LI, Mike Elias LIZARZABURU, Yosup REW, Joshua TAYGERLY, Yingcai WANG, Xuelei YAN, Ming YU, Jiang ZHU, Manuel ZANCANELLA, Xian Yun JIAO, Liusheng ZHU, Xianghong WANG, Julio C. MEDINA, Jason A. DUQUETTE, Jonathan B. HOUZE, Marc VIMOLRATANA, Mario G. CARDOZO, Alan C. CHENG
  • DIRECT SELECTION OF CELLS EXPRESSING HIGH LEVELS OF HETEROMERIC PROTEINS USING GLUTAMINE SYNTHETASE INTRAGENIC COMPLEMENTATION VECTORS
    Publication number: 20230048658
    Abstract: This invention relates to the general field of recombinant expression of polypeptides in animal cell culture. More specifically, the invention concerns improved selection of cells transfected with recombinantly engineered vectors designed to express polypeptides, in particular heteromultimeric polypeptides.
    Type: Application
    Filed: May 26, 2022
    Publication date: February 16, 2023
    Applicant: AMGEN INC.
    Inventors: Trent P. MUNRO, Neeraj Jagdish AGRAWAL, Kristine M. DARIS
  • Methods of treating heart failure with cardiac sarcomere activators
    Patent number: 11576910
    Abstract: Provided herein are methods of treating a subject with heart failure, comprising administering to the subject an initial dose of a cardiac sarcomere activator (CSA) for an initial time period, and subsequently administering to the subject a dose of the CSA based on the subject's plasma concentration of the CSA at the end of the initial time period.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: February 14, 2023
    Assignees: AMGEN INC., CYTOKINETICS, INC.
    Inventors: Narimon Honarpour, Fady Malik
  • Dosage regimen for administering a CD19xCD3 bispecific antibody to patients at risk for potential adverse effects
    Patent number: 11579142
    Abstract: A method for assessing the risk of potential adverse effects for a human patient receiving is provided. The method comprises determining the total B count in the patient, and identifying a B cell number indicative of a patient at risk of potential adverse effects from the antibody. The method further provides a dosing schedule for administering the antibody to the patient identified as at risk of potential adverse effects. Also provided is a pharmaceutical package or kit comprising a first dose and a second dose, and optionally a third dose, the CD19×CD3 bispecific antibody as defined in the methods/dosage regimen of the disclosure.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: February 14, 2023
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventor: Dirk Nagorsen
  • Method for making injectable pharmaceutical compositions
    Patent number: 11576856
    Abstract: The invention relates to methods for making injectable pharmaceutical compositions wherein particles present in the compositions are detected and analyzed, and the acceptance of the compositions is determined based on chemical and physical properties as well as toxicology and patient risks associated of the particles.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: February 14, 2023
    Assignee: AMGEN INC.
    Inventors: Andrew Phillip Spasoff, Susanne Therese Atkinson, Adrian Bennis, Erwin Freund
  • CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
    Publication number: 20230037742
    Abstract: The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.
    Type: Application
    Filed: April 2, 2021
    Publication date: February 9, 2023
    Applicant: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Peter KUFER, Tobias RAUM, Roman KISCHEL, Ralf Lutterbüse, Patrick HOFFMANN, Doris RAU, Susanne MANGOLD, Matthias KLINGER, Evelyne SCHALLER, Susanne HAUSMANN, Petra FLUHR, Carola STEIGER
  • INTERLEUKIN-2 IN COMBINATION WITH TNF RECEPTOR FAMILY MEMBERS FOR THE EXPANSION OF T-REGULATORY CELLS
    Publication number: 20230040604
    Abstract: Provided herein are combinations of an IL-2 molecule or mutein and a TNFR agonist, and complexes comprising IL-2/TNFR agonist molecules, such as Fc-bound IL-2/TNFR agonist molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are methods of making and using the compositions of the present invention.
    Type: Application
    Filed: December 17, 2020
    Publication date: February 9, 2023
    Applicant: AMGEN INC.
    Inventors: Ashutosh CHAUDHRY, Wenjun OUYANG
  • N-cyano-7-azanorbornane derivatives and uses thereof
    Patent number: 11572374
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: February 7, 2023
    Assignee: AMGEN INC.
    Inventors: John R. Butler, Daniel Erlanson, Russell Graceffa, Jeffrey Iwig, Joon Won Jeong, Ryan D. White, Yongwei Wu, Shuyan Yi, Xiao Mei Zheng, Jesse M. McFarland, Abhisek Banerjee